Payment overview · 2025
General Payments
$1,834.65
93 reported records · 19 companies
Healthcare provider profile · identity verified
James Schack, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BUTLER, KY · NPI 1508313594
Verified facts
What the public records show
CMS Open Payments records show James Schack, M.D. received $1,834.65 in general payments during 2025 across 93 reported records.
ABBVIE INC. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Kerendia, Mounjaro, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $362.20 | 19.7% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $217.96 | 11.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $213.18 | 11.6% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $163.27 | 8.9% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $152.46 | 8.3% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $104.46 | 5.7% | 6 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $101.19 | 5.5% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $85.88 | 4.7% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $81.60 | 4.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.56 | 4.0% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $66.65 | 3.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $55.48 | 3.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.14 | 2.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.38 | 1.8% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $21.29 | 1.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.97 | 1.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.93 | 0.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.12 | 0.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.93 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,834.65 | 93 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $249.72 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $217.96 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $217.96 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $217.96 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $196.82 | 15 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $152.46 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $124.62 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $104.46 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $103.93 | 7 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $101.19 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $99.31 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $96.80 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $88.13 | 6 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $85.88 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $81.60 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $66.65 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.34 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.08 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $55.48 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.64 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.32 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.38 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 44 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 211 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 20 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
211 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
125 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 439 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 275 | 81 |
| Omeprazole | Omeprazole | 264 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 245 | 61 |
| Lisinopril | Lisinopril | 223 | 63 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 211 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 50 |
| Prednisone | Prednisone | 189 | 141 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 185 | 60 |
| Losartan Potassium | Losartan Potassium | 156 | 48 |
| Metformin Hcl Er | Metformin Hcl | 146 | 42 |
| Gabapentin | Gabapentin | 141 | 34 |
| Trazodone Hcl | Trazodone Hcl | 129 | 34 |
| Jardiance | Empagliflozin | 125 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 33 |
| Buspirone Hcl | Buspirone Hcl | 115 | 31 |
| Furosemide | Furosemide | 115 | 46 |
| Ondansetron Odt | Ondansetron | 114 | 37 |
| Metformin Hcl | Metformin Hcl | 111 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 29 |
| Ipratropium Bromide | Ipratropium Bromide | 103 | 57 |
| Montelukast Sodium | Montelukast Sodium | 103 | 29 |
| Pregabalin | Pregabalin | 98 | 23 |
| Meloxicam | Meloxicam | 91 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 27 |
| Naproxen | Naproxen | 83 | 31 |
| Ozempic | Semaglutide | 80 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 78 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 20 |
| Amoxicillin | Amoxicillin | 63 | 48 |
| Cephalexin | Cephalexin | 63 | 55 |
| Simvastatin | Simvastatin | 63 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 58 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 23 |
| Carvedilol | Carvedilol | 56 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 20 |
| Farxiga | Dapagliflozin Propanediol | 54 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 16 |
| Potassium Chloride | Potassium Chloride | 51 | 13 |
| Sertraline Hcl | Sertraline Hcl | 49 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 37 |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 45 | 16 |
| Eliquis | Apixaban | 44 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | 17 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 42 | suppressed |
| Allopurinol | Allopurinol | 41 | 12 |
| Fluconazole | Fluconazole | 41 | 27 |
| Mirtazapine | Mirtazapine | 41 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | 13 |
| Famotidine | Famotidine | 35 | 13 |
| Levofloxacin | Levofloxacin | 35 | 32 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 20 |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Cefdinir | Cefdinir | 31 | 26 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 20 |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 27 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Vraylar | Cariprazine Hcl | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Misoprostol | Misoprostol | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,834.65 · 93 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, Kerendia, MOUNJARO, NEXLETOL, NURTEC ODT, Ohtuvayre, Omnipod, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error